dummy content

About the Meeting

The annual meeting will focus on acute myeloid leukemia, acute promeyelocytic leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome and multiple myeloma.

International and national experts will present the critical appraisal of emerging and existing data and its applicability in the day to day practice. An important focus of this meeting will be the trainees' education with the help of multi-disciplinary sessions addressing the diagnosis, prognostication and therapy of hematological cancers.

This meeting will showcase the data on acute leukemia's from the Indian centers.

The poster session will provide an opportunity to present data pertaining to diagnosis, treatment, novel finding and clinical outcomes in hematology cancers.

The unique aspect is the opportunity to showcase novel research concepts and ideas relevant to the country.

Day's Until

01234636
  • Days
  • Hours
  • Mins
  • Secs
  • Time until Friday, 16th August 2019

    Welcome Message

    Dear Colleagues

    Hematology Cancer Consortium invites you for the first annual meeting to be held in Kochi, on 16-18 August 2019.

    Hematology Cancer Consortium is a multi-center collaborative academic organization established with the aim to improve knowledge, standardize cost-effective treatment strategies and promote regionally relevant research in hematological cancers. In the first year of its existence the consortium has established collaborative database for the acute leukemia's and has started the process for conducting prospective investigator-initiated studies.

    The annual meeting will focus on acute myeloid leukemia, acute promeyelocytic leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome and multiple myeloma. International and national experts will present the critical appraisal of emerging and existing data and its applicability in the day to day practice. An important focus of this meeting will be the trainees' education with the help of multi-disciplinary sessions addressing the diagnosis, prognostication and therapy of hematological cancers. This meeting will showcase the data on acute leukemia's from the Indian centers. The poster session will provide an opportunity to present data pertaining to diagnosis, treatment, novel findings and clinical outcomes in hematological cancers. The unique aspect is the session focusing on novel research concepts and ideas relevant to the country. The best 5 posters will be awarded with a certificate and prize.

    The target audience for this meeting includes hematologists, medical oncologists, clinicians involved in management of hematological cancers, hematopathologists, pathologists, basic scientists with interest in hematological malignancies trainees, fellows, residents pursuing super-specialty courses in Hematology , Medical oncology and Pathology.

    We look forward to welcoming you in Kochi.

    dummy
    Name of Doctor

    Organizing Chairperson

    dummy
    Name of Doctor

    President

    dummy
    Name of Doctor

    Vice President

    dummy
    Name of Doctor

    Secretary

    About HCC

    Hematology Cancer Consortium is a multi-center collaborative academic organization established with the aim to improve knowledge, standardize cost-effective treatment strategies and promote regionally relevant research in hematological cancers. In the first year of its existence the consortium has established collaborative database for the acute leukemia's and has started the process for conducting prospective investigator-initiated studies.


    dummy
    dummy
    dummy
    dummy

    Achievement Awards

    What is Lorem Ipsum?

    Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

    What is Lorem Ipsum?

    Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

    What is Lorem Ipsum?

    Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

    What is Lorem Ipsum?

    Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

    International Speakers

    dummy

    Dr. Austin Kulasekararaj

    King's College Hospital NHS foundation trust
    dummy

    Dr. Charles Mullighan

    St Jude Children's Research Hospital
    dummy

    Dr. Daniel Pollyea

    University of Colorado, Denver
    dummy

    Dr. Harry Iland

    University of Sydney
    dummy

    Dr. Harry Erba

    Duke Cancer Center
    dummy

    Dr. Sundar Jagannath

    Mount Sinai Hospital
    dummy

    Dr. Timothy Hughes

    Royal Adelaide Hospital

    Meeting Secretariat

    Organizing Secretary: Dr. Manju Sengar
    CEO: Ms. Bhavisha Sanadhya
    Room 1116, 11th floor, Homi Bhabha Block, Tata Memorial Hospital,
    Dr. Ernest Borges Road, Parel, Mumbai 400 012
    E-Mail: meeting@hemecancer.org | bsanadhya@hemecancer.org
    Website: www.hemecancer.org
    Powered by iceIndia.in